Heejeong Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Heejeong Kim has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Yunjong Lee
Department of Pharmacology, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea
2 shared publications - Bo Am Seo
Department of Convergence Medicine, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea
1 shared publication - Byoung Dae Lee
Department of Neuroscience Kyung Hee University Seoul Republic of Korea
1 shared publication Donghoon Kim
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
1 shared publicationDoyeun Kim
Medicinal Bioconvergence Research Center, Yonsei University, Incheon 21983, Republic of Korea
1 shared publication- Elliot Hwejoon Lee
Brain Science Institute Korea Institute of Science and Technology Seoul Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 29 September 2026
- Published by Wiley in Advanced Science
- p. e78007
Developmentally Guided Differentiation of Ventral Midbrain Dopaminergic Cells Validated in Proteopathy‐Based Parkinson's Disease Models
Parkinson's disease (PD) involves progressive degeneration of nigrostriatal ventral midbrain dopaminergic (vmDA) neurons and Lewy body proteopathy, necessitating scalable, lineage‐faithful donor cells. However, variability in human pluripotent stem cell (hPSC) differentiation and incomplete ventral midbrain identity limit translational use. Here, we establish a developmentally guided differentiation protocol that reproducibly specifies EN1‐positive vmDA progenitors through temporally optimized SHH, WNT/β‐catenin, and FGF8 signaling. The resulting progenitors mature into vmDA neurons exhibiting stimulus‐dependent dopamine release and maturation‐associated pacemaking activity. Progenitors can be cryopreserved at a defined stage while retaining viability and neurogenic capacity. Functional validation was performed using complementary proteopathy‐based PD models. In vitro, optogenetic induction of α‐synuclein aggregation ( OASIS ) triggered robust aggregate formation and selective degeneration of TH‐positive vmDA neurons in both two‐dimensional cultures and three‐dimensional neurospheroids. In vivo, we established a conditional β23 proteopathy‐based PD mouse model exhibiting progressive nigrostriatal degeneration and motor impairment. Transplantation of hESC‐derived vmDA progenitors into advanced‐stage PD mice led to graft survival, differentiation into vmDA neurons, and significant motor improvement. Together, these findings define a robust vmDA differentiation framework validated across proteopathy‐based disease modeling and transplantation contexts, supporting its application in PD modeling and cell therapy.
- 29 September 2026
- Published by Wiley in Advanced Science
- p. e78007
Open AccessDevelopmentally Guided Differentiation of Ventral Midbrain Dopaminergic Cells Validated in Proteopathy‐Based Parkinson's Disease Models
Parkinson's disease (PD) involves progressive degeneration of nigrostriatal ventral midbrain dopaminergic (vmDA) neurons and Lewy body proteopathy, necessitating scalable, lineage‐faithful donor cells. However, variability in human pluripotent stem cell (hPSC) differentiation and incomplete ventral midbrain identity limit translational use. Here, we establish a developmentally guided differentiation protocol that reproducibly specifies EN1‐positive vmDA progenitors through temporally optimized SHH, WNT/β‐catenin, and FGF8 signaling. The resulting progenitors mature into vmDA neurons exhibiting stimulus‐dependent dopamine release and maturation‐associated pacemaking activity. Progenitors can be cryopreserved at a defined stage while retaining viability and neurogenic capacity. Functional validation was performed using complementary proteopathy‐based PD models. In vitro, optogenetic induction of α‐synuclein aggregation ( OASIS ) triggered robust aggregate formation and selective degeneration of TH‐positive vmDA neurons in both two‐dimensional cultures and three‐dimensional neurospheroids. In vivo, we established a conditional β23 proteopathy‐based PD mouse model exhibiting progressive nigrostriatal degeneration and motor impairment. Transplantation of hESC‐derived vmDA progenitors into advanced‐stage PD mice led to graft survival, differentiation into vmDA neurons, and significant motor improvement. Together, these findings define a robust vmDA differentiation framework validated across proteopathy‐based disease modeling and transplantation contexts, supporting its application in PD modeling and cell therapy.
- 11 November 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (569)
Amyloid-like oligomerization of AIMP2 contributes to α-synuclein interaction and Lewy-like inclusion
Pathological AIMP2 aggregation leads to α-synuclein inclusion and dopaminergic toxicity in Parkinson’s disease.
- 11 November 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (569)
Amyloid-like oligomerization of AIMP2 contributes to α-synuclein interaction and Lewy-like inclusion
Pathological AIMP2 aggregation leads to α-synuclein inclusion and dopaminergic toxicity in Parkinson’s disease.